Letaplimab
Letaplimab (IBI-188) is a human IgG4 anti-CD47 monoclonal antibody. CD47 is overexpressed on cancer cells, it is a ligand for SIRPα. Letaplimab enhances tumor cell phagocytosis[1].
Product Specifications
CAS Number
[2283356-07-8]
Product Name Alternative
IBI-188
UNSPSC
12352203
Target
Others
Type
Inhibitory Antibodies
Related Pathways
Others
Applications
Cancer-programmed cell death
Field of Research
Cancer
Assay Protocol
https://www.medchemexpress.com/letaplimab.html
Purity
95.00
Solubility
10 mM in DMSO
Smiles
[Letaplimab]
Molecular Weight
(142.38 kDa)
References & Citations
[1]Miao Miao, et al. A Phase 1b Study to Evaluate Safety and Efficacy of IBI188 in Combination with Azacitidine (AZA) As a First-Line Treatment in Subjects with Newly Diagnosed Higher Risk Myelodysplastic Syndrome. MYELODYSPLASTIC SYNDROMES-CLINICAL AND EPIDEMIOLOGICAL NOVEMBER 15, 2022.
Shipping Conditions
Dry Ice
Storage Conditions
Store at -80°C for 2 years
Scientific Category
Inhibitory Antibodies
Clinical Information
Phase 2
Available Sizes
Curated Selection
Explore Other Products
Discover premium biology products from our extensive collection of 20M+ items
MBS6335776-01 0.2 mL
POLR3B, NT (POLR3B, DNA-directed RNA polymerase III subunit RPC2, C128, DNA-directed RNA polymerase III 127.6kD polypeptide, DNA-directed RNA polymerase III subunit B) (Biotin)
Ask
View Details 
MBS6335776-02 5x 0.2 mL
POLR3B, NT (POLR3B, DNA-directed RNA polymerase III subunit RPC2, C128, DNA-directed RNA polymerase III 127.6kD polypeptide, DNA-directed RNA polymerase III subunit B) (Biotin)
Ask
View Details 